Posts

WuXi AppTec raises 2026 outlook after strong nine-month results

on
WuXi AppTec reported revenue of RMB 45.54 billion for the first nine months of 2026, up 38.6% year over year; continuing-operations revenue increased 46.3%. The company raised its 2026 revenue target to RMB 61.0–61.9 billion, from RMB 58.5–60.5 billion previously. It also lifted its continuing-operations growth outlook to 40–42%. Profit attributable to owners rose to RMB 19.16 billion, and continuing-operations backlog reached RMB 76.74 billion, up 36.4%. The results came despite U.S. regulatory and political uncertainty. WuXi was placed on the Defense Department’s Section 1260H list in June, but a U.S. court issued a preliminary injunction in August blocking enforcement of that designation while the case proceeds. The company also raised its adjusted free-cash-flow forecast to RMB 14.5–15.5 billion and plans RMB 8.0–8.5 billion in 2026 capital spending. Sources: WuXi AppTec Delivers Strong Q1-Q3 2026 Results and Further ... WuXi AppTec bucks DOD uncertainty through Q3, l...

Artiva ends AlloNK program and cuts 94% of staff

on

Novartis stands by Avidity deal after $1.9 billion del-desiran write-down

on

Incyte and Revolution Medicines look closely matched in early KRAS G12D pancreatic cancer data

on

Corxel plans Nasdaq listing via SPAC to fund oral obesity drug

on

Windward Bio files for Nasdaq IPO to fund clinical programs

on

Novartis warns MFN could reshape European drug launches

on

ESMO: Imfinzi–Padcev shows promise with less Padcev after surgery

on

J&J’s oral RIPTAC shows early activity in advanced prostate cancer

on

Lycia Therapeutics closes upsized $365.1 million IPO

on

BMS reports death in MS CAR-T trial and aims to restart studies

on

Merck–Kelun ADC shows substantial progression-free survival benefit in PD-L1-negative NSCLC

on

Imdelltra–Imfinzi combination shows major survival benefit in Phase 3 lung cancer trial

on